Pseudomyogenic
hemangioendothelioma was recognized as a distinctive entity under the name epithelioid sarcoma-like
hemangioendothelioma in 2003; in a series of 7 patients, Billings et al (1) described a tumor that lacked frank histologic evidence of vascular differentiation such as vascular channel formation and intracytoplasmic lumens; however, vascular differentiation was evident with the use of immunohistochemical stains.
Long-term outcomes following liver transplantation for hepatic
hemangioendothelioma: the UNOS experience from 1987 to 2005.
Infantile hepatic
hemangioendothelioma with elevated serum alphafetoprotein.
Clinical outcomes for systemic corticosteroids versus vincristine in treating kaposiform
hemangioendothelioma and tufted angioma.
Pseudomyogenic
hemangioendothelioma (PHE)--previously referred to as a fibroma-like variant of epithelioid sarcoma, given its morphological similarity to epithelioid sarcoma--is a rare and recently described endothelial tumor.
Massive hepatic
hemangioendothelioma and consumptive hypothyroidism.
Epithelioid
hemangioendothelioma (EHE) is a rare endothelial neoplasm first described by Weiss and Enzinger (1) in 1982.
In the borderline category, kaposiform
hemangioendothelioma is a childhood tumor that may be associated with thrombocytopenia and consumptive coagulopathy, whereas Kaposi sarcoma is most commonly encountered in the immunocompromised adult.
One case was that of epithelioid
hemangioendothelioma.
(8,9) Various terms are used to describe this lesion such as papillary fibroendothelioma, intravascular endothelioma, papillary proliferation of the endothelium, papillary endothelioma, hemangioendotheliome vegetant intravasculaire, l'endovasculite proliferante trombopoietique, intravenous atypical vascular proliferation, intravascular angiomatosis, IPEH, Masson's vegetant intravascular
hemangioendothelioma, Masson's pseudoangiosarcoma, intravascular endothelial hyperplasia, Masson's lesion, and papillary endothelial hyperplasia.
James Ewing first described Ewing's sarcoma in 1921 as a "diffuse
hemangioendothelioma of bone." Data show that this neoplasm "may be neuroectodermally derived from the primitive neural tissue" (9).
In the FNB group, eight patients (18.2%) required a second EUS (six pancreatic adenocarcinomas, one
hemangioendothelioma, and one benign).